Intraperitoneal/Peritoneal Dissemination Xenograft

  • Principle
  • Experimental Materials
  • Experimental Procedure
  • Troubleshooting

Materials Required

• PBS Buffer/Power

Principle

Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.

MCE has not independently verified the accuracy of these methods. They are for reference only.

Experimental Materials

Reagents and Chemicals:

• Phosphate-buffered saline (PBS): used for tumor cell suspension and injection vehicle preparation in peritoneal inoculation procedures;
• Cell culture media (e.g., standard growth medium for ovarian cancer cell lines): used for expansion of tumor cells prior to implantation;
• Trypsin or enzymatic dissociation reagents: used to detach adherent tumor cells before intraperitoneal injection preparation.

Antibodies, probes, dyes, or kits

• Luciferase reporter systems (luciferase-expressing SKOV3 or OVCAR-3 derivatives): used for in vivo bioluminescence imaging of peritoneal tumor burden;
• Fluorescent labeling systems (e.g., GFP-expressing tumor cells): used to visualize tumor dissemination and organ colonization in vivo.

Equipment and instruments

• Immunodeficient mouse strains (nude mice or SCID-based models): used as hosts for human tumor xenografts;
• In vivo imaging systems (bioluminescence/fluorescence imaging): used to monitor tumor progression and dissemination longitudinally;
• Intraperitoneal injection apparatus (syringes and fine-gauge needles): used to deliver tumor cells into the peritoneal cavity.

Experimental Procedure

• Preparation Steps: Human ovarian cancer cells (e.g., SKOV3 or SKOV3-derived variants) are expanded under standard in vitro culture conditions and harvested at exponential growth phase prior to implantation.

• Cells are enzymatically detached, washed, and resuspended in sterile buffer (commonly PBS) for intraperitoneal inoculation.

• For imaging-based models, cells are engineered to express luciferase or fluorescent proteins to enable longitudinal monitoring of tumor growth and peritoneal dissemination in vivo.

• Immunodeficient mice (e.g., nude or SCID strains) are acclimatized prior to tumor cell injection to ensure experimental stability and reduce physiological variability.

• Operation Steps: Tumor cells are introduced into the peritoneal cavity of immunodeficient mice via intraperitoneal injection, where they disseminate throughout the abdominal cavity and establish multiple tumor implants on peritoneal surfaces and visceral organs.

• Following implantation, tumor progression is monitored using imaging modalities such as bioluminescence imaging, which allows non-invasive quantification of tumor burden over time in luciferase-expressing models.

• In established models, peritoneal tumors exhibit heterogeneous distribution across the omentum, mesentery, and abdominal organs, reflecting site-dependent differences in adhesion, invasion, and microenvironmental interactions.

• Therapeutic interventions (e.g., intraperitoneal chemotherapy, biologics, or nanoparticles) can be administered via the same intraperitoneal route to directly target disseminated tumor sites and assess treatment efficacy in a clinically relevant delivery context.

• Data Acquisition and Analysis: Tumor burden is typically quantified using bioluminescence intensity or fluorescence signal distribution, which correlates with tumor cell viability and spatial dissemination within the peritoneal cavity.

• Survival analysis is commonly used as a primary endpoint in peritoneal xenograft studies, particularly in models evaluating therapeutic interventions, where treatment-induced changes in survival time reflect overall tumor control efficacy.

• Histological or macroscopic examination of peritoneal organs is used to confirm tumor implantation patterns and evaluate the extent of dissemination across abdominal structures.

Troubleshooting

Problem 1:

Low or inconsistent peritoneal tumor engraftment

Possible Cause:
Variability in tumor cell viability or implantation efficiency during intraperitoneal injection.

Literature-supported Solution:
Ensuring standardized preparation of viable tumor cells prior to intraperitoneal inoculation improves reproducibility of peritoneal dissemination patterns in xenograft models.

Problem 2:

Uneven or heterogeneous tumor dissemination within the peritoneal cavity

Possible Cause:
Differential adhesion and microenvironmental interactions at distinct peritoneal sites.

Literature-supported Solution:
Use of luciferase-tagged tumor cells and longitudinal imaging helps identify spatial heterogeneity and validate consistent dissemination patterns across experimental groups.

Problem 3:

Low sensitivity in tumor burden detection

Possible Cause:
Insufficient signal from imaging reporters in early-stage peritoneal disease.

Literature-supported Solution:
Bioluminescence imaging systems enable detection and quantification of tumor progression over time, improving sensitivity for early peritoneal metastasis assessment.

Problem 4:

Reduced survival difference between control and treatment groups

Possible Cause:
Rapid tumor progression overwhelming therapeutic window in aggressive peritoneal dissemination models.

Literature-supported Solution:
Adjusting experimental timing and using survival endpoints in combination with imaging-based tumor burden measurements improves resolution of treatment effects in peritoneal xenograft studies.

Share